Properties
What is it?
Composition BLOCIUM B12 Injection form: Each ampoule with solvent contains: Potassium diclofenac — 75.00 mg Betamethasone sodium phosphate — 2.63 mg Benzyl alcohol — 0.06 mg Anhydrous disodium phosphate — 4.98 mg Sodium hydroxide — q.s. pH 8.4 Methylparaben — 2.4 mg Propylparaben — 0.45 mg Propylene glycol — 576 mg Water for injection — q.s. 3.0 ml Each lyophilized vial-ampoule contains: Hydroxocobalamin — 10.00 mg Excipients: Mannitol — 87.00 mg Indications Acute inflammatory rheumatic conditions; Lumbosciatica; Cervical brachialgia; Polyradiculoneuropathy. Contraindications Hypersensitivity to the active ingredients of the preparation; Hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs; Active gastroduodenal ulcer; Acute renal failure; Liver failure; Severe decompensated heart failure; Arterial hypertension; Systemic mycoses; Latent tuberculosis; Gout; A, B and non A-B hepatitis and other viral infections; Anticoagulant therapy; Pregnancy and lactation. Dosage and administration 1-2 vials per day, only by deep intramuscular injection. The contents of the ampoule should be mixed with the vial and shaken gently. The duration of treatment depends on the patient's response and medical criteria. It should be emphasized that prolonged corticosteroid therapy for more than 2 weeks carries the risk of developing corticosuprarenal insufficiency, manifested by suppression of ACTH secretion and adrenal atrophy. In case of prolonged treatment, the dose should be gradually reduced to avoid the above-mentioned complications. It is not recommended to use BLOCIUM B12 injection for more than 3 days. Pregnancy and lactation Unless there is a specific indication, BLOCIUM B12 is not used during pregnancy, especially during the last trimester of gestation, as diclofenac may suppress uterine contractility and cause premature closure of the ductus arteriosus. Corticosteroids pass into breast milk, so their use is not recommended during this period. Possible side effects The following reactions have been observed with parenteral administration of the preparation: Hyperpigmentation or hypopigmentation, skin and subcutaneous atrophy, sterile abscesses; Isolated cases of acute renal failure, hematuria and proteinuria; Isolated cases of leukopenia, hemolytic anemia and agranulocytosis; Arterial hypertension, congestive heart failure and palpitations; Sodium retention, edema, potassium excretion and hypokalemic alkalosis; Muscle weakness, steroid myopathy, reduction of muscle mass, osteoporosis, vertebral compression fractures, femoral or humeral head fractures, pathological fractures of long bones; Menstrual irregularities, cushingoid state, growth retardation in children, adrenal insufficiency, which develops particularly during stressful situations such as trauma, surgery, systemic diseases. Reduced tolerance to carbohydrates, increased requirement for insulin and oral hypoglycemic agents in diabetic patients; Posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos and tinnitus. Negative nitrogen balance due to protein catabolism. Overdose In case of overdose, gastric lavage with induced vomiting is necessary. Packaging 5 vials-ampoules of lyophilized powder and 5 ampoules of solvent. Storage Store in a cool, dry place, at a temperature of 15-25C, out of reach of children. Dispensing Pharmaceutical product group II, dispensed with prescription form N3. Manufactured in Argentina by LABORATORIOS CASASCO, Buenos Aires. Email: [email protected]